Literature DB >> 28393558

Supraventricular tachycardia and acute confusion following ingestion of e-cigarette fluid containing AB-FUBINACA and ADB-FUBINACA: a case report with quantitative analysis of serum drug concentrations.

Rex Pui Kin Lam1, Magdalene Huen Yin Tang2, Siu Chung Leung3, Yeow Kuan Chong2, Matthew Sik Hon Tsui3, Tony Wing Lai Mak2.   

Abstract

BACKGROUND: AB-FUBINACA and ADB-FUBINACA are structurally similar synthetic cannabinoids with potent CB1 receptor agonistic effects. Very little is known about their pharmacology and toxicology.
OBJECTIVE: To report a case of supraventricular tachycardia and acute confusion after ingestion of e-cigarette fluid containing AB-FUBINACA and ADB-FUBINACA, with quantitative analysis of the serum drug concentrations. CASE REPORT: A healthy 24-year-old man ingested two drops of e-cigarette fluid which were later found to contain AB-FUBINACA and ADB-FUBINACA. Within 30 min of ingestion, he became somnolent, confused, and agitated, with palpitation and vomiting. On arrival to the emergency department, a short run of supraventricular tachycardia was noted, which resolved spontaneously. Bedside urine immunoassay failed to detect recreational drugs. Laboratory blood tests showed mild hypokalemia. Exposure to AB-FUBINACA and ADB-FUBINACA was confirmed analytically, with serum concentrations of 5.6 ng/mL and 15.6 ng/mL, respectively, in the blood sample collected on presentation. The patient recovered uneventfully with supportive treatment and was discharged 22 h after admission. DISCUSSION: AB-FUBINACA and ADB-FUBINACA are orally bioavailable with rapid onset of toxicity after ingestion. In this case, supraventricular tachycardia was likely the result of exposure to AB-FUBINACA and ADB-FUBINACA. The serum concentrations of AB-FUBINACA and ADB-FUBINACA were higher than those previously reported in fatal cases.
CONCLUSION: In the context of acute poisoning, the presence of unexplained tachyarrhythmias, confusion, and a negative recreational drug screen should prompt clinicians to consider synthetic cannabinoid toxicity as a differential diagnosis.

Entities:  

Keywords:  Synthetic cannabinoids; cardiac arrhythmias; designer drug; novel psychoactive substances; toxicity

Mesh:

Substances:

Year:  2017        PMID: 28393558     DOI: 10.1080/15563650.2017.1307385

Source DB:  PubMed          Journal:  Clin Toxicol (Phila)        ISSN: 1556-3650            Impact factor:   4.467


  11 in total

1.  The Psychoactive Surveillance Consortium and Analysis Network (PSCAN): the first year.

Authors:  Andrew A Monte; Andrew Hopkinson; Jessica Saben; Shelby K Shelton; Stephen Thornton; Aaron Schneir; Adam Pomerleau; Robert G Hendrickson; Ann M Arens; Jon B Cole; James Chenoweth; Spencer Martin; Axel Adams; Samuel D Banister; Roy R Gerona
Journal:  Addiction       Date:  2019-11-25       Impact factor: 6.526

2.  Cannabinoid-like effects of five novel carboxamide synthetic cannabinoids.

Authors:  Michael B Gatch; Michael J Forster
Journal:  Neurotoxicology       Date:  2018-11-12       Impact factor: 4.294

Review 3.  Reports of Adverse Events Associated with Use of Novel Psychoactive Substances, 2017-2020: A Review.

Authors:  Amanda L A Mohr; Barry K Logan; Melissa F Fogarty; Alex J Krotulski; Donna M Papsun; Sherri L Kacinko; Marilyn A Huestis; Jeri D Ropero-Miller
Journal:  J Anal Toxicol       Date:  2022-07-14       Impact factor: 3.220

4.  Coma, Seizures, Atrioventricular Block, and Hypoglycemia in an ADB-FUBINACA Body-Packer.

Authors:  Nicholas Nacca; Rachel Schult; Robert Loflin; Adam Weltler; Rachel Gorodetsky; Sherri Kacinko; Jeffery Moran; Alex Krotulski; Timothy Wiegand
Journal:  J Emerg Med       Date:  2018-10-05       Impact factor: 1.484

5.  Review of the many faces of synthetic cannabinoid toxicities.

Authors:  Azita Alipour; Puja Baldev Patel; Zaheera Shabbir; Stephen Gabrielson
Journal:  Ment Health Clin       Date:  2019-03-01

Review 6.  Overview of Synthetic Cannabinoids ADB-FUBINACA and AMB-FUBINACA: Clinical, Analytical, and Forensic Implications.

Authors:  Carolina Lobato-Freitas; Andreia Machado Brito-da-Costa; Ricardo Jorge Dinis-Oliveira; Helena Carmo; Félix Carvalho; João Pedro Silva; Diana Dias-da-Silva
Journal:  Pharmaceuticals (Basel)       Date:  2021-02-25

Review 7.  Health effects of electronic cigarette (e‑cigarette) use on organ systems and its implications for public health.

Authors:  Radhika Seiler-Ramadas; Isabell Sandner; Sandra Haider; Igor Grabovac; Thomas Ernst Dorner
Journal:  Wien Klin Wochenschr       Date:  2020-07-20       Impact factor: 1.704

8.  Man vs. man-made marijuana: A case of drug-induced posterior reversible encephalopathy syndrome (PRES) due to K2, a ynthetic cannabinoid (SCB).

Authors:  Priyanka Parajuli; Manjari Rani Regmi; Odalys Estefania Lara-Garcia; Ismael Abu Limon; Alan Deckard
Journal:  J Community Hosp Intern Med Perspect       Date:  2020-08-02

Review 9.  A Systematic Literature Review of E-Cigarette-Related Illness and Injury: Not Just for the Respirologist.

Authors:  Anna Tzortzi; Melpo Kapetanstrataki; Vaso Evangelopoulou; Panagiotis Beghrakis
Journal:  Int J Environ Res Public Health       Date:  2020-03-27       Impact factor: 3.390

10.  In Vitro Interaction of AB-FUBINACA with Human Cytochrome P450, UDP-Glucuronosyltransferase Enzymes and Drug Transporters.

Authors:  Sunjoo Kim; Dong Kyun Kim; Yongho Shin; Ji-Hyeon Jeon; Im-Sook Song; Hye Suk Lee
Journal:  Molecules       Date:  2020-10-08       Impact factor: 4.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.